Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04762875 · ClinicalTrials.gov registry record · Phase 2
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
A Phase 2 study, sponsored by Ensoma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT04762875: Clinical Trial Phase 2 study, sponsored by Ensoma.
NCT04762875 is a Phase 2 study that was terminated before completion, run by Ensoma. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04762875, a Phase 2 study, was terminated before completion, sponsored by Ensoma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This research study tests a new medicine for mobilizing stem cells so they can be collected and used for allogeneic stem cell transplant for treatment of hematological malignancies. MGTA-145, the new medicine, will be given with plerixafor.
Primary Outcome
Number of subjects with adequate number of hematopoietic stem cells (≥ 2.0 x 10\^6 CD34+ cells/kg) in one apheresis setting.
Interventions
- BIOLOGICAL MGTA-145
- BIOLOGICAL Plerixafor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-06-16 |
| Est. Completion | 2022-03-14 |
| Phase | Phase 2 |
Why NCT04762875 stopped before completion
NCT04762875 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which MGTA-145 is the first listed.
NCT04762875 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04762875 about?
NCT04762875 is a clinical study titled "MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies". This research study tests a new medicine for mobilizing stem cells so they can be collected and used for allogeneic stem cell transplant for treatment of hematological malignancies. MGTA-145, the new medicine, will be given with plerixafor.
What is the current status of trial NCT04762875?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2021-06-16. Estimated completion is 2022-03-14.
What interventions are being tested in trial NCT04762875?
The interventions under investigation include: MGTA-145 (BIOLOGICAL), Plerixafor (BIOLOGICAL).
Who is sponsoring clinical trial NCT04762875?
This trial is sponsored by Ensoma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04762875's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI